Verastem, Inc. (VSTM)
| Market Cap | 1.12B +96.1% |
| Revenue (ttm) | 87.53M +3,995.7% |
| Net Income | -202.70M |
| EPS | -2.28 |
| Shares Out | 121.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,959,024 |
| Open | 8.04 |
| Previous Close | 7.71 |
| Day's Range | 7.77 - 9.73 |
| 52-Week Range | 3.43 - 10.82 |
| Beta | 0.39 |
| Analysts | Strong Buy |
| Price Target | 17.22 (+86.57%) |
| Est. Earnings | Nov 3, 2026 |
About VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine ki... [Read more]
Financial Performance
In 2025, Verastem's revenue was $30.91 million, an increase of 209.14% compared to the previous year's $10.00 million. Losses were -$209.47 million, 60.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for VSTM stock is "Strong Buy." The 12-month stock price target is $17.22, which is an increase of 86.57% from the latest price.
News
Verastem price target raised to $22 from $18 at Alliance Global
Alliance Global raised the firm’s price target on Verastem (VSTM) to $22 from $18 and keeps a Buy rating on the shares following the investor day. The company issued updated…
Verastem price target raised to $19 from $14 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on Verastem (VSTM) to $19 from $14 and keeps an Outperform rating on the shares after the company announced results…
Verastem price target raised to $24 from $18 at BTIG
BTIG raised the firm’s price target on Verastem (VSTM) to $24 from $18 and keeps a Buy rating on the shares. The firm cites the company’s much anticipated data from…
Verastem price target raised to $13 from $11 at Jefferies
Jefferies analyst Faisal Khurshid raised the firm’s price target on Verastem (VSTM) to $13 from $11 and keeps a Buy rating on the shares after the company issued “a comprehensive…
Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug
Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.
Verastem trading halted, volatility trading pause
09:42 EDT Verastem (VSTM) trading halted, volatility trading pause
Verastem Transcript: Study update
VS-7375 showed confirmed responses in pancreatic cancer and early activity in colorectal and lung cancer, alongside high dose intensity and predominantly low-grade GI events. Frontline pancreatic Phase III was FDA-approved, with launch expected by year-end and frontline lung and colorectal studies planned for H1 next year.
Verastem Press release: Study update
Verastem issued a press release on October 14, 2026, disclosing material business information to investors.
Verastem Slides: Study update
Verastem has posted slides in relation to its latest quarterly earnings report, which was published on October 14, 2026.
Verastem up 20% to $8.94 after results from TARGET-D 101 trial, CEO change
06:16 EDT Verastem (VSTM) up 20% to $8.94 after results from TARGET-D 101 trial, CEO change
Verastem prices 30.94M shares at $8.00 in public offering
Verastem (VSTM) Oncology announced the pricing of an underwritten offering of 30,937,500 shares of its common stock at an offering price of $8.00 per share, and in lieu of common…
Verastem announces results from TARGET-D 101 Phase 1/2 clinical trial
Verastem (VSTM) Oncology announced positive initial efficacy and updated safety and tolerability data in first multi-tumor clinical data update from the ongoing TARGET-D 101 Phase 1/2 clinical trial e...
Verastem appoints Michel Bailey as CEO, effective January 1
Verastem Oncology (VSTM) announced that Michael P. Bailey has been appointed President and CEO, effective January 1, 2027. Bailey will also continue to serve on the Company’s Board of Directors.
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed wi...
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that Mich...
VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 demonstrates robust clinical activity with favorable safety and tolerability in KRAS G12D-mutated pancreatic, lung and colorectal cancers.
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant...
Verastem announces data from analysis of Phase 2 RAMP 201 trial
Verastem (VSTM) Oncology announced data from a new molecular profiling and tumor biomarker analysis of the Phase 2 RAMP 201 clinical trial of avutometinib plus defactinib in patients with recurrent…
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--New RAMP 201 Molecular Profiling and External Control Arm Analyses Supports Outcomes for Avutometinib Plus Defactinib in Recurrent LGSOC.
Verastem announces publication of RAMP 201 study in Gynecologic Oncology journal
Verastem (VSTM) Oncology announced that Gynecologic Oncology, the official journal of the Society of Gynecologic Oncology, has published two-year long-term results from the Phase 2 RAMP 201 study eval...
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Long-term RAMP 201 results published in Gynecologic Oncology reinforce durable clinical benefit and manageable safety profile in recurrent LGSOC.
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Verastem to present late-breaking oral presentation of RAMP 201 LGSOC molecular profiling and tumor biomarker analysis at IGCS 2026.
Verastem initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of Verastem (VSTM) with an Outperform rating.
Verastem Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Key programs include a commercial therapy for KRAS-mutated ovarian cancer and the VS-7375 KRAS G12D inhibitor, with phase II and III trials advancing in pancreas, lung, and colorectal cancers. Upcoming data and confirmatory studies aim to expand indications and demonstrate best-in-class efficacy. Major data readouts are expected in the next year.